Insider Trading Alert - UHS, MDSO And ARO Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 1, 2015, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $181.50 to $4,800,000.00.

Highlighted Stocks Traded by Insiders:

Universal Health Services (UHS) - FREE Research Report

Gibbs Lawrence S., who is Director at Universal Health Services, sold 1,393 shares at $129.62 on June 1, 2015. Following this transaction, the Director owned 1,436 shares meaning that the stake was reduced by 49.24% with the 1,393-share transaction.

The shares most recently traded at $130.83, up $1.21, or 0.93% since the insider transaction. Historical insider transactions for Universal Health Services go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 9,521
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 9,521
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 9,521

The average volume for Universal Health Services has been 736,500 shares per day over the past 30 days. Universal Health Services has a market cap of $11.9 billion and is part of the health care sector and health services industry. Shares are up 17.77% year-to-date as of the close of trading on Monday.

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, behavioral health centers, surgical hospitals, ambulatory surgery centers, and radiation oncology centers. The stock currently has a dividend yield of 0.31%. The company has a P/E ratio of 22.5. Currently, there are 12 analysts who rate Universal Health Services a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on UHS - FREE

TheStreet Quant Ratings rates Universal Health Services as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Universal Health Services Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Medidata Solutions (MDSO) - FREE Research Report

Taylor Robert, who is Director at Medidata Solutions, sold 5,048 shares at $56.81 on June 1, 2015. Following this transaction, the Director owned 54,494 shares meaning that the stake was reduced by 8.48% with the 5,048-share transaction.

The shares most recently traded at $56.35, down $0.46, or 0.82% since the insider transaction. Historical insider transactions for Medidata Solutions go as follows:

  • 4-Week # shares bought: 2,400
  • 4-Week # shares sold: 22,153
  • 12-Week # shares bought: 2,400
  • 12-Week # shares sold: 62,153
  • 24-Week # shares bought: 2,400
  • 24-Week # shares sold: 74,098

The average volume for Medidata Solutions has been 494,300 shares per day over the past 30 days. Medidata Solutions has a market cap of $3.2 billion and is part of the technology sector and computer software & services industry. Shares are up 22.35% year-to-date as of the close of trading on Monday.

Medidata Solutions, Inc. provides cloud-based clinical development solutions for life sciences in the United States and internationally. The company offers applications and data analytics for clinical development. The company has a P/E ratio of 414.4. Currently, there are 7 analysts who rate Medidata Solutions a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDSO - FREE

TheStreet Quant Ratings rates Medidata Solutions as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, robust revenue growth, good cash flow from operations, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Medidata Solutions Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Aeropostale (ARO) - FREE Research Report

Hirtler-Garvey Karin, who is Director at Aeropostale, bought 20,000 shares at $1.90 on June 1, 2015. Following this transaction, the Director owned 196,620 shares meaning that the stake was boosted by 11.32% with the 20,000-share transaction.

The shares most recently traded at $1.84, down $0.06, or 3.26% since the insider transaction. Historical insider transactions for Aeropostale go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 7,721
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 7,721
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 7,721

The average volume for Aeropostale has been 1.7 million shares per day over the past 30 days. Aeropostale has a market cap of $150.3 million and is part of the services sector and retail industry. Shares are down 26.29% year-to-date as of the close of trading on Monday.

Aeropostale, Inc. operates as a specialty retailer of casual apparel and accessories for 14 to 17 year-old young women and men. It operates through two segments, Retail Stores and E-Commerce, and International Licensing. Currently, there are no analysts who rate Aeropostale a buy, 3 analysts rate it a sell, and 11 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARO - FREE

TheStreet Quant Ratings rates Aeropostale as a sell. The company's weaknesses can be seen in multiple areas, such as its generally high debt management risk, disappointing return on equity, poor profit margins and generally disappointing historical performance in the stock itself. Get the full Aeropostale Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Video: Jim Cramer on Netflix, Disney, Intel, Micron and Goldman Sachs

Video: Jim Cramer on Netflix, Disney, Intel, Micron and Goldman Sachs

Jim Cramer Weighs In on Intel CEO Resignation

Jim Cramer Weighs In on Intel CEO Resignation

Stocks Tumble as Dow Heads for Eighth Straight Drop

Stocks Tumble as Dow Heads for Eighth Straight Drop

Jim Cramer: I Think Deregulation Will Produce Very Good Earnings for Banks

Jim Cramer: I Think Deregulation Will Produce Very Good Earnings for Banks

Jim Cramer on Micron: Listen to the Conference Call

Jim Cramer on Micron: Listen to the Conference Call